CUSIP: 49705R105
Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
38,578,902
-
Share change
-
-1,472,760
-
Total reported value
-
$54,009,394
-
Put/Call ratio
-
76%
-
Price per share
-
$1.40
-
Number of holders
-
55
-
Value change
-
-$5,570,966
-
Number of buys
-
23
-
Number of sells
-
41
Quarterly Holders Quick Answers
What is CUSIP 49705R105?
CUSIP 49705R105 identifies KNTE - KINNATE BIOPHARMA INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2023
-
Previous quarter:
Q2 2023
Recent filing periods for CUSIP 49705R105:
Institutional Holders of KINNATE BIOPHARMA INC - COM (KNTE) as of Q3 2023
As of 30 Sep 2023,
KINNATE BIOPHARMA INC - COM (KNTE) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,578,902 shares.
The largest 10 holders included
Foresite Capital Management IV, LLC, ORBIMED ADVISORS LLC, Foresite Capital Management V, LLC, Nextech Invest Ltd., Vida Ventures Advisors, LLC, Lynx1 Capital Management LP, VIKING GLOBAL INVESTORS LP, CITADEL ADVISORS LLC, VANGUARD GROUP INC, and Novo Holdings A/S.
This page lists
55
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.